230 related articles for article (PubMed ID: 29426769)
21. Multifunctional Desferrichrome Analogues as Versatile
Adams CJ; Wilson JJ; Boros E
Mol Pharm; 2017 Aug; 14(8):2831-2842. PubMed ID: 28665620
[TBL] [Abstract][Full Text] [Related]
22. Head-to-head comparison of DFO* and DFO chelators: selection of the best candidate for clinical
Chomet M; Schreurs M; Bolijn MJ; Verlaan M; Beaino W; Brown K; Poot AJ; Windhorst AD; Gill H; Marik J; Williams S; Cowell J; Gasser G; Mindt TL; van Dongen GAMS; Vugts DJ
Eur J Nucl Med Mol Imaging; 2021 Mar; 48(3):694-707. PubMed ID: 32889615
[TBL] [Abstract][Full Text] [Related]
23. Radiolabelling of the octadentate chelators DFO* and oxoDFO* with zirconium-89 and gallium-68.
Brandt M; Cowell J; Aulsebrook ML; Gasser G; Mindt TL
J Biol Inorg Chem; 2020 Aug; 25(5):789-796. PubMed ID: 32661784
[TBL] [Abstract][Full Text] [Related]
24. Trastuzumab-conjugated oxine-based ligand for [
Southcott L; Wharton L; Rousseau J; Merkens H; Yang H; Bénard F; Orvig C
J Inorg Biochem; 2022 Oct; 235():111936. PubMed ID: 35878576
[TBL] [Abstract][Full Text] [Related]
25. Novel Bifunctional Cyclic Chelator for (89)Zr Labeling-Radiolabeling and Targeting Properties of RGD Conjugates.
Zhai C; Summer D; Rangger C; Franssen GM; Laverman P; Haas H; Petrik M; Haubner R; Decristoforo C
Mol Pharm; 2015 Jun; 12(6):2142-50. PubMed ID: 25941834
[TBL] [Abstract][Full Text] [Related]
26.
Heskamp S; Raavé R; Boerman O; Rijpkema M; Goncalves V; Denat F
Bioconjug Chem; 2017 Sep; 28(9):2211-2223. PubMed ID: 28767228
[TBL] [Abstract][Full Text] [Related]
27. Lysine-Directed Site-Selective Bioconjugation for the Creation of Radioimmunoconjugates.
Sarrett SM; Rodriguez C; Rymarczyk G; Hosny MM; Keinänen O; Delaney S; Thau S; Krantz BA; Zeglis BM
Bioconjug Chem; 2022 Sep; 33(9):1750-1760. PubMed ID: 35946495
[TBL] [Abstract][Full Text] [Related]
28. 89Zr immuno-PET: comprehensive procedures for the production of 89Zr-labeled monoclonal antibodies.
Verel I; Visser GW; Boellaard R; Stigter-van Walsum M; Snow GB; van Dongen GA
J Nucl Med; 2003 Aug; 44(8):1271-81. PubMed ID: 12902418
[TBL] [Abstract][Full Text] [Related]
29. Octadentate Zirconium(IV)-Loaded Macrocycles with Varied Stoichiometry Assembled From Hydroxamic Acid Monomers using Metal-Templated Synthesis.
Tieu W; Lifa T; Katsifis A; Codd R
Inorg Chem; 2017 Mar; 56(6):3719-3728. PubMed ID: 28245117
[TBL] [Abstract][Full Text] [Related]
30. Macrocycle-Based Hydroxamate Ligands for Complexation and Immunoconjugation of
Boros E; Holland JP; Kenton N; Rotile N; Caravan P
Chempluschem; 2016 Mar; 81(3):274-281. PubMed ID: 27630807
[TBL] [Abstract][Full Text] [Related]
31. Investigation of Zr(IV) and 89Zr(IV) complexation with hydroxamates: progress towards designing a better chelator than desferrioxamine B for immuno-PET imaging.
Guérard F; Lee YS; Tripier R; Szajek LP; Deschamps JR; Brechbiel MW
Chem Commun (Camb); 2013 Feb; 49(10):1002-4. PubMed ID: 23250287
[TBL] [Abstract][Full Text] [Related]
32. Linear Desferrichrome-Linked Silicon-Rhodamine Antibody Conjugate Enables Targeted Multimodal Imaging of HER2 in Vitro and in Vivo.
Ahn SH; Thach D; Vaughn BA; Alford VM; Preston AN; Laughlin ST; Boros E
Mol Pharm; 2019 Mar; 16(3):1412-1420. PubMed ID: 30714739
[TBL] [Abstract][Full Text] [Related]
33. A High-Denticity Chelator Based on Desferrioxamine for Enhanced Coordination of Zirconium-89.
Sarbisheh EK; Salih AK; Raheem SJ; Lewis JS; Price EW
Inorg Chem; 2020 Aug; 59(16):11715-11727. PubMed ID: 32799484
[TBL] [Abstract][Full Text] [Related]
34. Immuno-PET Imaging of CD30-Positive Lymphoma Using 89Zr-Desferrioxamine-Labeled CD30-Specific AC-10 Antibody.
Rylova SN; Del Pozzo L; Klingeberg C; Tönnesmann R; Illert AL; Meyer PT; Maecke HR; Holland JP
J Nucl Med; 2016 Jan; 57(1):96-102. PubMed ID: 26514172
[TBL] [Abstract][Full Text] [Related]
35. Alternative chelator for ⁸⁹Zr radiopharmaceuticals: radiolabeling and evaluation of 3,4,3-(LI-1,2-HOPO).
Deri MA; Ponnala S; Zeglis BM; Pohl G; Dannenberg JJ; Lewis JS; Francesconi LC
J Med Chem; 2014 Jun; 57(11):4849-60. PubMed ID: 24814511
[TBL] [Abstract][Full Text] [Related]
36. Standardized methods for the production of high specific-activity zirconium-89.
Holland JP; Sheh Y; Lewis JS
Nucl Med Biol; 2009 Oct; 36(7):729-39. PubMed ID: 19720285
[TBL] [Abstract][Full Text] [Related]
37. Measuring the pharmacodynamic effects of a novel Hsp90 inhibitor on HER2/neu expression in mice using Zr-DFO-trastuzumab.
Holland JP; Caldas-Lopes E; Divilov V; Longo VA; Taldone T; Zatorska D; Chiosis G; Lewis JS
PLoS One; 2010 Jan; 5(1):e8859. PubMed ID: 20111600
[TBL] [Abstract][Full Text] [Related]
38. Di-macrocyclic terephthalamide ligands as chelators for the PET radionuclide zirconium-89.
Pandya DN; Pailloux S; Tatum D; Magda D; Wadas TJ
Chem Commun (Camb); 2015 Feb; 51(12):2301-3. PubMed ID: 25556851
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of a 3-hydroxypyridin-2-one (2,3-HOPO) Based Macrocyclic Chelator for (89)Zr(4+) and Its Use for ImmunoPET Imaging of HER2 Positive Model of Ovarian Carcinoma in Mice.
N Tinianow J; Pandya DN; Pailloux SL; Ogasawara A; Vanderbilt AN; Gill HS; Williams SP; Wadas TJ; Magda D; Marik J
Theranostics; 2016; 6(4):511-21. PubMed ID: 26941844
[TBL] [Abstract][Full Text] [Related]
40. What is the Best Radionuclide for Immuno-PET of Multiple Myeloma? A Comparison Study Between
Bailly C; Gouard S; Guérard F; Chalopin B; Carlier T; Faivre-Chauvet A; Remaud-Le Saëc P; Bourgeois M; Chouin N; Rbah-Vidal L; Tripier R; Haddad F; Kraeber-Bodéré F; Bodet-Milin C; Chérel M
Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31137758
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
